$NTLA

Gene-editing stocks fell Wednesday after Anthropic's AI model, Claude, identified a phage enzyme system with traits similar to CRISPR. CRISPR Therapeutics (CRSP) dropped 6%, Intellia (NTLA) 3%, Beam (BEAM) 6%, Prime Medicine (PRME) 12%, and Editas Medicine (EDIT) 8%. The discovery, called ART, links an RNA-to-DNA enzyme with repeating DNA and a mystery protein in bacteria-infecting viruses. CRISPR pioneer Feng Zhang called the finding intriguing but unproven.

Intellia Therapeutics (NTLA) awaits FDA decision on lonvo-z for hereditary angioedema (HAE) on March 10, with Phase III data showing 87% attack-rate reduction. The company is preparing for commercial launch, though pricing is undecided. Intellia also advances its TTR amyloidosis study and reports $630M in cash, with a $300M debt facility for funding into 2028.

Intellia Therapeutics (NTLA) outlined a two-track strategy at the Morgan Stanley conference. The FDA accepted its biologics license application for lonvo-z, with a PDUFA date of March 10, 2025. The company reported strong HAE data, including an 87% reduction in attack rate. Intellia has $630M in cash and expects to fund operations into 2028. It is preparing a targeted launch for lonvo-z and is advancing its TTR amyloidosis program, which faces design and competitive questions.

Intellia Therapeutics (NTLA) secured a $400M credit facility with OrbiMed, drawing $75M initially. The remaining $325M is contingent on milestones. The facility has a 9.15% minimum interest rate. NTLA has $628.4M in cash but reported a $106.6M Q2 net loss. The financing supports potential U.S. launch of lonvo-z and other programs.

Intellia Therapeutics (NTLA) announced the FDA accepted and granted priority review to its BLA for lonvoguran ziclumeran, a CRISPR-based therapy for hereditary angioedema (HAE). A decision is expected by March 2027. The therapy showed an 87% reduction in attacks in a phase III study. NTLA shares have risen 41.7% year-to-date. The company also has another CRISPR therapy, nexiguran ziclumeran, in development with Regeneron (REGN).

Wedbush analyst David Nierengarten maintained a Neutral rating on Intellia Therapeutics (NTLA) but raised the price target from $12.00 to $13.00, an 8.33% increase. GuruFocus values NTLA at $13.26, suggesting a 3.9% undervaluation, while insiders sold $506,590 in shares over the past three months. The company's GF Score is 70/100, indicating fair fundamentals but low profitability.

Intellia Therapeutics' hereditary angioedema treatment, Lonvo-Z, received FDA Priority Review. If approved, it would be the first in vivo CRISPR therapy. The FDA set a PDUFA target action date of March 10, 2027. Lonvo-Z showed an 87% reduction in attacks in a Phase 3 study. Intellia's stock has risen over 35% year-to-date, with ARK Invest recently increasing its stake.

Intellia Therapeutics (NTLA) shares rose after the FDA granted priority review for its CRISPR-based therapy lonvo-z, targeting hereditary angioedema. The company's P/S ratio is 24.91, below its historical median, suggesting market expectations of future growth. GuruFocus' GF Value™ estimates NTLA is 4.8% undervalued at $12.63 per share, with a GF Score™ of 70/100.

Intellia Therapeutics (NTLA) shares rose 8% after the FDA accepted its Biologics License Application with Priority Review for lonvoguran ziclumeran (lonvo-z) for hereditary angioedema. The FDA set a target action date of March 10, 2027. The application is supported by Phase 3 trial data showing an 87% reduction in mean monthly attacks compared with placebo. If approved, lonvo-z would be the first in vivo CRISPR-based therapy for HAE.

Intellia Therapeutics (NTLA) announced FDA acceptance and Priority Review of its Biologics License Application for lonvo-z, a potential first-in-class CRISPR-based therapy for hereditary angioedema (HAE). The application is supported by Phase 3 HAELO trial data showing an 87% reduction in mean monthly attacks versus placebo. If approved, lonvo-z could become the first one-time in vivo CRISPR therapy for HAE, with a PDUFA target action date of March 10, 2027.